← Back to Search

Adult patients for Solid Tumors

Phase 2
Waitlist Available
Research Sponsored by Bayer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 57 months
Awards & highlights

Study Summary

This trial will observe patients who are already taking regorafenib in order to collect safety data and assess tolerability of the drug.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 57 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 57 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Frequency of protocol-defined adverse events (AEs)
Frequency of serious adverse events (SAEs)
Severity of protocol-defined adverse events (AEs)
+1 more
Secondary outcome measures
Frequency of dose modifications

Trial Design

1Treatment groups
Experimental Treatment
Group I: Adult patientsExperimental Treatment1 Intervention
Adult patients from completed Bayer-sponsored regorafenib trials who are benefitting from regorafenib treatment.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BAY73-4506 (Regorafenib, Stivarga)
2019
Completed Phase 2
~10

Find a Location

Who is running the clinical trial?

BayerLead Sponsor
2,233 Previous Clinical Trials
25,326,314 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What other purposes has this medication been shown to help with?

"This treatment is often used for the treatment of liver cancer. It can also be prescribed to treat various other conditions, such as those that have previously been treated with anti-VEGF therapy or those that are receiving amino acid supplementation."

Answered by AI

Does this clinical trial represent a new development in treatment?

"At present, there are 109 ongoing trials for this medication in 33 countries and 1327 cities. The first trial began in 2007 and was sponsored by Baxter Healthcare Corporation. That initial study completed its Phase 4 drug approval stage with 4640 patients enrolled. Since then, an additional 119 studies have concluded."

Answered by AI

Are there any risks associated with this treatment that patients should be made aware of?

"The safety of this intervention was estimated to be a 2. This is due to the fact that, while Phase 2 trials offer some preliminary evidence regarding safety, there is no data at this time to support efficacy claims."

Answered by AI

Are there still places available in this clinical trial for new participants?

"Unfortunately, this trial is no longer looking for patients. However, when it was active, the study was originally posted on April 2nd, 2019 and last updated on November 9th, 2023. There are currently two trials actively recruiting participants with solid cancers and 109 other trials for this treatment that are still seeking patients."

Answered by AI

How many people fit the necessary qualifications to join this experiment?

"Unfortunately, this particular trial is no longer looking for patients. The listing was created on April 2nd, 2019 but the most recent update was on November 9th, 2020. Out of the 109 other trials exploring this treatment, only 2 are actively recruiting right now."

Answered by AI

Have there been other similar medical studies in the past that used this treatment?

"At the moment, 109 clinical trials are underway to study this intervention. Out of those, 11 are in Phase 3. The vast majority of these studies are taking place in Tampa, Florida; however, 8144 different locations worldwide are running trials for this treatment."

Answered by AI
~1 spots leftby Mar 2025